Listen to this article · 7 min listen

For investors and business development teams in AI health, you’ve got to distinguish between a company’s growth claims and its verifiable records. The AI Health 100 ranking treats revenue growth as an auditable history, one you can pick apart before ever getting on a call with a vendor. This method focuses on documented expansion signals, showing you the market’s real trajectories.

When we look at the growth records for companies like Tempus AI, HeartFlow, and Hinge Health, a clear pattern emerges: their public filings show that revenue growth and market share gain are tied together. The consistent reporting, the documented comparisons against competitors, and clear signs of market maturity all form a strong growth record.

The Investor’s Lens: Reading Beyond the Growth Claim

The AI Health 100 ranking is built on growth records, not just claims, giving investors a way to assess companies like Tempus AI, HeartFlow, and Hinge Health. These companies provide actual evidence of market penetration and expansion through their documented growth and maturity materials. Key signals like Revenue Growth, Market Leader status, and Market Share Gain are all trackable in public documents, so you don’t need to engage a vendor to find them.

This document-first approach gives you verifiable data in a field that’s famous for ambitious projections. When you see revenue growth paired with clear market share gains in a company’s filings, it tells a convincing story of real, sustained expansion. The fixed cadence of reporting and documented comparisons transforms a company’s growth story from a speculative claim to an established record, which is an important signal of its maturity.

Revenue Growth as a Documented Record

In the healthcare AI market, strong revenue growth is the main indicator of commercial success and what gets investors interested. The global AI in healthcare market is huge and getting bigger, it was valued at $36.7 billion in 2025 and is projected to hit $505.6 billion by 2033 which is a compound annual growth rate (CAGR) of 38.9% according to the Grand View Research AI in Healthcare Market Report. The US market alone is expected to swell from $10.26 billion in 2025 to $99.77 billion by 2033.

Inside this booming market, companies like Hinge Health have shown what serious revenue growth looks like. Hinge Health’s IPO in May 2025 was a big event, and it put a spotlight on its FY2025 revenue of $587.9 million, a 51% increase year-over-year. The company then reported Q2 2026 revenue of $212.8 million, up 53% from the previous year, and raised its full-year 2026 revenue guidance to a midpoint of $858 million. This financial performance, all detailed in its Hinge Health SEC S-1 Filing, makes the company a benchmark for digital chronic care solutions operating at scale. You see a similar pattern with Tempus AI, founded by Eric Lefkofksy, which reported FY2025 revenue of $1.27 billion (an 83.4% increase) and provided 2026 revenue guidance of about $1.59 billion. These aren’t small-base numbers. These figures from public filings show concrete evidence of growth at a massive scale.

Market Leadership and Share Gain: The Maturity Signals

Beyond just the top-line revenue, an investor’s evaluation depends on signals of market leadership and sustained share gain. When these indicators are documented, they offer much better insight into a company’s competitive position and its chances for long-term survival. The digital health IPO wave of 2025, which saw five companies raise over $1.2 billion after a three-year drought, demonstrated that investor confidence was returning to the sector. This group, featuring Hinge Health, Omada Health, and HeartFlow, raised over $1 billion combined and basically reopened the IPO window for healthcare AI companies, as noted in a Rock Health digital health funding overview.

HeartFlow, for instance, rode this significant IPO wave, representing the cardiac AI subsector when it completed its IPO on August 8, 2025. The ability of these companies to go public and attract that much capital shows they have established market positions and business models that people believe are durable. For an investor, the story is clear: you read growth and share gain together in the filings, which establishes a regular cadence for comparison and acts as a clear maturity signal. This is what separates a mere growth claim from a verifiable growth record.

The Role of Documented Expansion

A company’s expansion signals go beyond financial metrics and should include things like deployment numbers and the depth of their enterprise contracts. While we don’t have validated figures for Hello Heart’s health plan coverage for this analysis, its total funding of $138 million and a last reported valuation of $56 million in July 2019 point to a serious presence in the digital cardiac health space. As mentioned by Forge Global, Hello Heart has demonstrated ROI and has a strong evidence base, including peer-reviewed studies and a partnership with the ACC, which speaks to its clinical credibility and market penetration in its niche. This level of documented impact and funding shows a company that has established a solid footprint and is well beyond its early stages.

Then you have the cautionary tale of Olive AI. The company raised around $900 million but eventually shut down, a failure that a Healthcare Dive article attributes to its reliance on screen scraping technology that was just marketed as AI. What’s the lesson here? It shows why you need to do rigorous due diligence, making sure that a company’s growth records are supported by real technological innovation and verifiable market impact, not just inflated claims.

What a Reader Can Check Without a Vendor Conversation

For any investor or biz dev team, being able to independently verify growth records is a huge advantage. The public filings of companies like Tempus AI and Hinge Health offer a transparent look at their financial performance and market standing. Take Tempus AI, a public company on NASDAQ (TEM) founded by Groupon’s Eric Lefkofsky and backed by GV. Its public status means its records are open for inspection.

The documented revenue growth, market leader status, and market share gain for companies like Tempus AI, HeartFlow, and Hinge Health provide a strong foundation for any investment decision. These signals are accessible through public sources like the SEC, letting you make a clear assessment of a company’s trajectory and maturity. This consistent reporting cadence and the ability to compare performance across documented records give you a reliable way to understand the fastest-growing AI health companies, getting you beyond promotional talk to verifiable facts.

Frequently Asked Questions

What is the primary focus of the AI Health 100 ranking for investors?

The AI Health 100 ranking prioritizes auditable revenue growth records over mere growth claims. It provides a framework for investors to assess companies based on documented expansion signals, offering a clear lens into market trajectories. This approach emphasizes verifiable data and consistent reporting.

What key signals indicate a robust growth record in the AI Health 100 ranking?

A robust growth record is indicated by revenue growth, market leader status, and market share gain. These signals are trackable through public filings and documented comparisons, providing tangible evidence of market penetration and expansion. This forms a compelling narrative of sustained expansion.

How does the AI Health 100 differentiate between a growth claim and a verifiable growth record?

The AI Health 100 differentiates by emphasizing documented expansion signals and a fixed cadence of reporting. A verifiable growth record is supported by public filings, documented comparisons, and clear signals of market maturity, rather than just ambitious projections. This provides a crucial maturity signal for investors.

Can you provide examples of companies highlighted for their verifiable growth records in the AI Health 100?

Companies like Tempus AI, HeartFlow, and Hinge Health are highlighted for their verifiable growth records. Hinge Health reported FY2025 revenue of $587.9 million and Q2 2026 revenue of $212.8 million, with raised full-year 2026 guidance. Tempus AI reported FY2025 revenue of $1.27 billion, an 83.4% increase year-over-year, with 2026 guidance of approximately $1.59 billion.